{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:45:19Z","timestamp":1768643119739,"version":"3.49.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T00:00:00Z","timestamp":1504051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Health and Social Policy","award":["EC10-320"],"award-info":[{"award-number":["EC10-320"]}]},{"name":"Lluita contra la SIDA Foundation","award":["B-904"],"award-info":[{"award-number":["B-904"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182547","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T17:45:44Z","timestamp":1504115144000},"page":"e0182547","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-5422","authenticated-orcid":true,"given":"Jose A.","family":"Mu\u00f1oz-Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"Garolera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"P\u00e9rez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crisanto","family":"D\u00edez-Quevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmina R.","family":"Fumaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the TRIANT-TE Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study","volume":"75","author":"RK Heaton","year":"2010","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/QAD.0b013e3283354a7b","article-title":"Cognitive dysfunction in HIV patients despite long-standing suppression of viremia","volume":"24","author":"S Simioni","year":"2010","journal-title":"AIDS"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1258\/095646204773557794","article-title":"Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART","volume":"15","author":"V Tozzi","year":"2004","journal-title":"Int J STD AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S1355617704102130","article-title":"The impact of HIV-associated neuropsychological impairment on everyday functioning","volume":"10","author":"RK Heaton","year":"2004","journal-title":"J Int Neuropsychol Soc"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/apc.2009.0300","article-title":"Neurocognition, health-related reading literacy, and numeracy in medication management for HIV infection","volume":"24","author":"D Waldrop-Valverde","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1089\/aid.2005.21.706","article-title":"Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART","volume":"21","author":"V Tozzi","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.131","article-title":"Adjuvant therapies for HIV-associated neurocognitive disorders","volume":"1","author":"JL McGuire","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"ref8","article-title":"Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer&apos;s disease and Parkinson&apos;s disease dementia","volume":"16","author":"CH Sadowsky","year":"2014","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref9","first-page":"6","article-title":"Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action","volume":"127","author":"J Poirier","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e21954","DOI":"10.1371\/journal.pone.0021954","article-title":"Rivastigmine lowers A\u03b2 and increases sAPP\u03b1 levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons","volume":"6","author":"JA Bailey","year":"2011","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bbadis.2016.01.013","article-title":"Role of P-glycoprotein in mediating rivastigmine effect on amyloid-\u03b2 brain load and related pathology in Alzheimer&apos;s disease mouse model","volume":"1862","author":"LA Mohamed","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/iub.1106","article-title":"Amyloid beta accumulation in HIV-1-infected brain: The role of the blood brain barrier","volume":"65","author":"IE Andr\u00e1s","year":"2013","journal-title":"IUBMB Life"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11481-014-9546-0","article-title":"Role of HIV in amyloid metabolism","volume":"9","author":"M Ortega","year":"2014","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1212\/WNL.0b013e3182815497","article-title":"Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study","volume":"80","author":"S Simioni","year":"2013","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1097\/01.aids.0000244208.49123.1b","article-title":"HNRC Group. Lithium improves HIV-associated neurocognitive impairment","volume":"20","author":"SL Letendre","year":"2006","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/13550280902758973","article-title":"Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment","volume":"15","author":"G Schifitto","year":"2009","journal-title":"J Neurovirol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"A Antinori","year":"2007","journal-title":"Neurology"},{"key":"ref18","first-page":"45","article-title":"Neurologic complications of HIV disease and their treatment","volume":"18","author":"SL Letendre","year":"2010","journal-title":"Top HIV Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1089\/aid.2006.0120","article-title":"Assessing self-reported adherence to HIV therapy by questionnaire: The SERAD (self-reported adherence) study","volume":"23","author":"JA Mu\u00f1oz-Moreno","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref20","article-title":"Wechsler Adult Intelligence Scale","author":"D Wechsler","year":"1997"},{"key":"ref21","article-title":"Clinical Neuropsychology: Current Status and Applications","author":"RM Reitan","year":"1974"},{"key":"ref22","article-title":"Symbol Digit Modalities Test","author":"A Smith","year":"1973"},{"key":"ref23","article-title":"California Verbal Learning Test","author":"DC Delis","year":"2000"},{"key":"ref24","article-title":"Stroop Color and Word Test: A Manual for Clinical and Experimental Uses","author":"CJ Golden","year":"1978"},{"key":"ref25","article-title":"Wisconsin Card Sorting Test (WCST) Manual Revised and Expanded","author":"RK Heaton","year":"1993"},{"key":"ref26","article-title":"Tower of London-Drexel University (TOLDX)","author":"WC Culbertson","year":"2001"},{"key":"ref27","article-title":"Multilingual Aphasia Examination","author":"AL Benton","year":"1994"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/107319119900600204","article-title":"Norms for letter and category fluency: Demographic corrections for age, education, and ethnicity","volume":"6","author":"JA Gladsjo","year":"1999","journal-title":"Assessment"},{"key":"ref29","article-title":"Grooved Pegboard. The Halstead-Reitan Extended Neuropsychological Test Battery","author":"RM Reitan","year":"1985"},{"key":"ref30","unstructured":"Wechsler D. Escala de Inteligencia Wechsler para Adultos (WAIS-III) (3\u00aa Ed.). Madrid: TEA Ediciones; 1999."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.acn.2007.01.022","article-title":"Trail Making test in traumatic brain injury, schizophrenia, and normal ageing: Sample comparisons and normative data","volume":"22","author":"JA Peri\u00e1\u00f1ez","year":"2007","journal-title":"Arch Clin Neuropsychol"},{"key":"ref32","unstructured":"Smith, A. Test de S\u00edmbolos y D\u00edgitos (SDMT). Madrid: TEA Ediciones; 2002."},{"key":"ref33","unstructured":"Golden CH. Stroop. Test de Colores y Palabras. Madrid: TEA Ediciones; 2001."},{"key":"ref34","first-page":"167","article-title":"Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming","volume":"14","author":"TN Tombaugh","year":"1999","journal-title":"Arch Clin Neuropsychol"},{"key":"ref35","unstructured":"European AIDS Clinical Society GUIDELINES. Version 8.0. October 2015. Algorithm for Diagnosis and Management of HIV-Associated Neurocognitive Impairment in Persons without Obvious Confounding Conditions, pp. 66. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html\" xlink:type=\"simple\">http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html<\/ext-link>. Last access 12 October 2016."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/00005650-199108000-00011","article-title":"A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection","volume":"29","author":"AW Wu","year":"1991","journal-title":"Med Care"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"AS Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/QAI.0b013e31829e1408","article-title":"A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: the NEU screen","volume":"63","author":"JA Mu\u00f1oz-Moreno","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref39","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson&apos;s disease dementia and cognitive impairment in Parkinson&apos;s disease","volume":"14","author":"M Rolinski","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref40","first-page":"CD009132","article-title":"Cholinesterase inhibitors for mild cognitive impairment","volume":"12","author":"TC Russ","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.intell.2011.03.001","article-title":"What cognitive abilities are involved in trail-making performance?","volume":"39","author":"TA Salthouse","year":"2011","journal-title":"Intelligence"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T23:57:37Z","timestamp":1659398257000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182547"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,30]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182547","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,30]]}}}